Twist Bioscience (TWST) Set to Announce Quarterly Earnings on Friday

Twist Bioscience (NASDAQ:TWSTGet Free Report) will announce its 12/31/2023 earnings results before the market opens on Friday, February 2nd. Analysts expect the company to announce earnings of ($0.80) per share for the quarter. Investors that are interested in registering for the company’s conference call can do so using this link.

Twist Bioscience (NASDAQ:TWSTGet Free Report) last posted its earnings results on Friday, November 17th. The company reported ($0.81) earnings per share for the quarter, beating the consensus estimate of ($0.92) by $0.11. Twist Bioscience had a negative net margin of 83.48% and a negative return on equity of 30.14%. The firm had revenue of $66.95 million during the quarter, compared to the consensus estimate of $63.35 million. During the same quarter last year, the firm earned ($0.91) EPS. The firm’s revenue for the quarter was up 16.8% on a year-over-year basis. On average, analysts expect Twist Bioscience to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Twist Bioscience Stock Performance

Twist Bioscience stock opened at $32.40 on Thursday. Twist Bioscience has a fifty-two week low of $11.46 and a fifty-two week high of $39.74. The firm has a 50 day moving average price of $32.38 and a 200 day moving average price of $24.67. The company has a market capitalization of $1.87 billion, a PE ratio of -9.00 and a beta of 1.55.

Institutional Investors Weigh In On Twist Bioscience

Institutional investors have recently modified their holdings of the company. Mercer Global Advisors Inc. ADV purchased a new stake in shares of Twist Bioscience during the 2nd quarter worth $218,000. Ameritas Investment Partners Inc. lifted its position in Twist Bioscience by 16.0% in the first quarter. Ameritas Investment Partners Inc. now owns 4,293 shares of the company’s stock valued at $212,000 after acquiring an additional 591 shares during the last quarter. Advisor Group Holdings Inc. lifted its position in Twist Bioscience by 95.9% in the fourth quarter. Advisor Group Holdings Inc. now owns 7,862 shares of the company’s stock valued at $187,000 after acquiring an additional 3,848 shares during the last quarter. AQR Capital Management LLC purchased a new stake in Twist Bioscience in the first quarter valued at $180,000. Finally, Rockefeller Capital Management L.P. lifted its position in Twist Bioscience by 124.7% in the first quarter. Rockefeller Capital Management L.P. now owns 10,988 shares of the company’s stock valued at $165,000 after acquiring an additional 6,099 shares during the last quarter.

Analyst Ratings Changes

Several analysts recently weighed in on the stock. Barclays lifted their target price on shares of Twist Bioscience from $30.00 to $45.00 and gave the company an “overweight” rating in a report on Thursday, January 25th. The Goldman Sachs Group raised shares of Twist Bioscience from a “neutral” rating to a “buy” rating and raised their price target for the company from $25.00 to $45.00 in a research report on Wednesday, January 17th.

View Our Latest Stock Report on TWST

Twist Bioscience Company Profile

(Get Free Report)

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.

See Also

Earnings History for Twist Bioscience (NASDAQ:TWST)

Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.